gene editing

Killing cancer by stealth: Gene editing firm Precision Bio secures another FDA approval to advance drugs

Posted by WRAL TechWire | Jan 22, 2021

The Durham clinical-stage biotechnology company has received U.S. Food and Drug Administration approval to advance its new drug for patients with relapsed/refractory non-Hodgkin Lymphoma.

‘Dedicated to Improving Life:’ Inside Precision Biosciences’ huge deal with Eli Lilly

Posted by WRAL TechWire | Nov 24, 2020

Global pharmaceutical giant Eli Lilly and Company is interested in Durham-based Precision Biosciences’ genome editing technology and it’s putting its money where its interest is. Here’s a look at the mega deal between the two firms.

Gene-editing of crops requires greater transparency, NCSU researchers say

Posted by WRAL TechWire | Nov 23, 2020

Researchers at North Carolina State University call for a coalition of biotech industry, government and non-government organizations, trade organizations, and academic experts to work together to provide basic information about gene-edited crops to lift the veil on how plants or plant products are modified and provide greater transparency on the presence and use of gene editing in food supplies.

Triangle gene editing startup AgBiome spins off group to life science portfolio firm

Posted by WRAL TechWire | Nov 16, 2020

AgBiome, a Triangle startup focusing on gene editing technologies, is spinning off part of its operations.

Precision Bio CEO finds comfort in gene-editing patent wins despite $26M loss

Posted by WRAL TechWire | Nov 11, 2020

Precision BioSciences on Tuesday reported a loss of $26 million in its third quarter, but its CEO stressed positive news in patent victories and research progress. Here’s what happened.

Inside the $4B AskBio deal, the third largest buyout ever for an NC bioscience firm

Posted by WRAL TechWire | Oct 27, 2020

Asklepios BioPharmaceutical (AskBio), a pioneering gene therapy company born in Chapel Hill 19 years ago and supported in its early years by the North Carolina Biotechnology Center, will be acquired by Bayer AG, Here’s a look at the deal and the company’s history.

AskBio exec: Gene editing firm chose $4B Bayer offer over other firms, also going public

Posted by WRAL TechWire | Oct 26, 2020

Bayer’s $2 billion upfront price plus the same amount offered based on milestone achievements wasn’t the only financial windfall leaders at AskBio were considering before agreeing to Bayer’s terms, says a company exec.

Gene editing shows promise as tool to fight neuro disorder in babies, UNC study finds

Posted by WRAL TechWire | Oct 23, 2020

Babies born with a faulty maternal copy of the UBE3A gene will develop Angelman syndrome, a severe neurodevelopmental disorder with no cure and limited treatments. Now, for the first time, scientists at the UNC School of Medicine show that gene editing and gene therapy techniques can be used to restore UBE3A in human neuron cultures and treat deficits in an animal model of Angelman syndrome.